| Document |
Document Title |
|
WO/2005/077868A2 |
The invention relates to congeneric, halogenated, fluorinated, aromatic compounds (I), (II), (IIIa) or (IIIb), (IV), (V), (VI) or (VII), in which A and B represent phenyl groups, L represents an oxygen atom, sulphur atom or an alkene gro...
|
|
WO/2005/075401A1 |
The invention relates to a method for producing 2,5-dimethylphenyl acetic acid by reacting p-xylol with chloroacetyl chloride to form 2-chloro-1-(2,5-dimethylphenyl) ethanone, which reacts with the compound of formula (II) to form the co...
|
|
WO/2005/075451A1 |
Disclosed is a highly reliable material for organic electroluminescent devices which has high luminance and high luminous efficiency, hardly deteriorates in emission, and is excellent in use and storage at high temperatures. Also disclos...
|
|
WO/2005/072681A2 |
N-Bicyclic amides and derivatives thereof and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndrom...
|
|
WO/2005/070885A1 |
bis-Bicyclic amides and derivatives thereof and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndr...
|
|
WO/2005/061459A1 |
The present invention relates to biaryl sulfonamides of the formula 1: wherein: R1 is H or Cl-.C6 a]kyl; R2 is H, C I -C6 alkyl, (CH2)nR2' , phenyl, or benzyl; n is 0-6; R2'is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl; R 3 is, in...
|
|
WO/2005/056509A1 |
The present case relates to a process for the purification of lactide from a crude lactide vapour product stream which process comprises a rectification/condensation step leading to a lactide-enriched condensate.
|
|
WO/2005/051895A1 |
Disclosed are &dgr -amino-&gammad -hydroxy-&ohgr -aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and ...
|
|
WO/2005/047249A1 |
The present invention relates to compounds which are CCR-5 receptor antagonists of the general formula (I) wherein R1, R2, R3, R4, Ra, Rb, Rc, Rd, X, m and n are as defined herein. The invention further comprises pharmaceutical compositi...
|
|
WO/2005/046683A1 |
Compounds are disclosed that have a formula represented by the following: Formula (I) The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals in...
|
|
WO/2005/042513A1 |
There is provided a compound having Formula (I) R1-Z-R2 Formula (I) wherein R1 is an optionally substituted phenyl ring; R2 is or comprises an optionally substituted aromatic ring; and Z is -X-Y-L- or -Y-X-L- wherein either X is selected...
|
|
WO/2005/040127A1 |
The present invention relates to novel compounds accelerating the activity of Peroxisome proliferator-activated receptor gamma (PPAR&gammad ) and alpha (PPAR&agr ), processes of preparing the same, and pharmaceutical compositions contain...
|
|
WO/2005/040355A2 |
The invention provides compounds and methods for inhibition of kinases, such as those of the TAO family, more specifically KIAA1361, TAO, and JIK kinases. The invention provides compounds for modulating protein kinase enzymatic activity ...
|
|
WO/2005/040138A1 |
This invention is related to compounds of general formula (I) wherein X is oxygen or sulphur or a NR7 group; R1 is C3-C8 alkyl, or C1-C8 alkyl substituted by phenoxy or phenyl, both phenoxy or phenyl being optionally substituted by one o...
|
|
WO/2005/033093A1 |
7,8-Bicyclic-chroman derivatives of Formula I, wherein the substituents are defined as in the specification or the pharmaceutically acceptable salts thereof, are disclosed. They are useful for the treatment of inflammatory disorders, neu...
|
|
WO/2005/033092A1 |
The invention relates to novel chroman derivatives, stereoisomers and pharmaceutically acceptable salts of Formula I, wherein the substituents are as defined in the specification. They are useful in the treatment of disorders mediated by...
|
|
WO/2005/032544A1 |
The invention relates the method of treatment or amelioration of mitochondrial disorders such as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitoch...
|
|
WO/2005/030704A1 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell pr...
|
|
WO/2005/030694A1 |
The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.
|
|
WO/2005/030213A1 |
Compounds of Formula (IA), IB), IC), and (ID) wherein R1, R2, R3, R4, R5, and R6 are as respectively defined herein for Formula (IA), (IB), (IC), and (ID), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions con...
|
|
WO/2005/023793A2 |
The present invention provides for the simplified, direct synthesis of di-heteroatom containing cyclic organic compounds by forming an aqueous mixture of material of the formula (I); wherein X and Y are heteroatoms which may be the same ...
|
|
WO/2005/019159A1 |
A process for producing corresponding &agr -aminooxyketones in high yield and with high enantioselectivity, that is, a process for the production of optically active &agr -aminooxyketone derivatives represented by the general formula (1)...
|
|
WO/2005/019192A1 |
The invention relates to novel urea derivatives which inhibit tyrosinkinases, especially TIE-2, and Raf kinases and which are used in the treatment of tumors.
|
|
WO/2005/016862A1 |
A compound represented by the formula (I)[In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C2 to C6 in the aromatic ring (E) independently represent a ring-constituting car...
|
|
WO/2005/013928A1 |
The present invention provides a method and composition for promoting hair growth in a mammal which comprises a prostaglandin compound having two hetero atoms at the 15 position as an active ingredient thereof.
|
|
WO/2005/014539A2 |
HMGCo-A reductase inhibitor compounds of formula (I) useful as hypocholesterolemic and hypolipidemic compounds are provided. Also provided are pharmaceutical compositions of the compounds. Methods of making and methods of using the compo...
|
|
WO/2005/012280A1 |
The present invention is related to alkynyl aryl carboxamides of Formula (I’) and use thereof for the treatment and/or prevention of an inflammatory disorder, obesity and/or metabolic disorders mediated by insulin resistance or hypergl...
|
|
WO/2005/012284A1 |
A 4,5-dihydronaphtho[1,2-b]thiophene derivative represented by the formula (1) (wherein R1 represents C1-10 1-hydroxyalkyl or C1-10 acyl, and R2 and R3 are separately bonded in respective positions selected among the 6-, 7-, 8-, and 9-po...
|
|
WO/2005/012228A1 |
The invention relates to novel o ptical recording materials that comprise specific and in some cases novel diketone enamines or metal chelates thereof and that have excellent recording and playback quality especially ata wavelength of 35...
|
|
WO/2005/012179A2 |
This invention is to provide supercritical water or subcritical water with which chemical substances, in particular, harmful organic substances difficult to decompose, such as p-dichlorobenzene and PCB, can be oxidized into harmless subs...
|
|
WO/2005/009985A1 |
A method for producing trimethylene carbonate poly(trimethylene carbonate which comprises (a) introducing liquid poly(trimethylene carbonate) and an optional catalyst into a wiped film evaporator reactor under a vacuum 15 kPa or less, sa...
|
|
WO/2005/009984A1 |
An acetal of formula (I) is disclosed, whereby the groups R1 to R6, independently = H, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl or tert.-butyl, n = 0 or 1 and, in the location of a dotted line between two C atom...
|
|
WO/2005/009104A2 |
The present invention is directed to hepatocyte nuclear factor 4a (HNF-4a) receptor modulator compounds. This invention is also directed to pharmaceutical compositions containing such compounds as well as methods of using such compounds ...
|
|
WO/2005/007621A2 |
This invention describes compounds useful as ubiquitin ligase inhibitors. The compounds of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also provides f...
|
|
WO/2005/000832A1 |
By using a charge-transporting thin film which is made of a charge-transporting varnish containing, as an electron-acceptor material, a 1,4-benzodioxane sulfonic acid compound represented by the formula (1) below especially in an OLED de...
|
|
WO/2005/000233A2 |
The present invention is directed to compounds having the structure (I) wherein R1, R2, R3, R4, R5 and m are as defined herein. The compounds of this invention are novel therapeutic agents for the treatment of cancer, metabolic diseases ...
|
|
WO/2004/113314A1 |
The present invention relates to optically active dihydroxy hexanoate derivatives, boronate esters of formula (IIa) which are useful intermediates for the synthesis of HMG-CoA enzyme inhibitors like atorvastatin, cerivastatin, rosuvastat...
|
|
WO/2004/110418A2 |
Disclosed herein are carbonyl compounds of Formula (I), (II) or (III), and others as described herein. Also disclosed are methods of treating disease, such as cancer, neurological disorders, including polyglutamine-repeat disorders, anem...
|
|
WO/2004/108733A1 |
Prodrugs of 6-β-hydroxymethylpenicillanic acid sulfone having the structure wherein R is H or methyl, each X is methylene, and Y is 0, or wherein R is H, each X is 0 and Y is methylene, and solvates thereof are disclosed. Also disclosed...
|
|
WO/2004/108697A1 |
The invention relates to protected 5,7-dihydroxy-4,4-dimethyl-3-oxoheptanoic acid esters and 5,7-dihydroxy-2-alkyl-4,4-dimethyl-3-oxoheptanoic acid esters for synthesizing epothilones and derivatives thereof, and to methods for producing...
|
|
WO/2004/103560A1 |
The present invention concerns a catalytic composition comprising a catalyst effective for catalysing asymmetric hydrogenation reactions, which catalyst requires acid activation, an acidic material effective for activating the catalyst, ...
|
|
WO/2004/101483A1 |
A novel compound for overcoming diseases including diabetes, obesity and neuroses such as nerve damage, Alzheimer and Parkinson's disease; and a medical agent comprising the same. In particular, there are provided a compound of the follo...
|
|
WO/2004/099173A1 |
Novel glycerol cyclic pyruvate derivates were prepared and demonstrated to inhibit the binding of an immobilized D-proline derivative to serum amyloid P component (SAP) have been prepared. As such, the compounds of the invention are usef...
|
|
WO/2004/092106A2 |
Process for preparing alkoxy- and aryloxy-phenols, comprising oxidizing the ketone of formula (I) with peracids to give the corresponding ester of formula (II) which is then hydrolysed to give the corresponding aryloxy- or alkoxy-phenol.
|
|
WO/2004/089927A1 |
Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases o...
|
|
WO/2004/083153A1 |
A process for production of an allyl and/or methallyl ether of a tri or polyhydric alcohol is disclosed. Said process comprises (i) subjecting at least one cyclic formal of a tri or polyhydric alcohol to allylation, (ii) subjecting obtai...
|
|
WO/2004/080379A2 |
The invention relates to extracts of Pangium edule, advantageously from seeds, and lignanes of formula I. The invention also relates to the use thereof as a medicament which inhibits cathepsins or which has an antinecrotic effect.
|
|
WO/2004/080947A1 |
A compound represented by the following general formula (I), its salt, its solvate or its N-oxide or prodrugs thereof: (I) wherein R1 and R2 represent each an optionally substituted cyclic group, etc.; W is a spacer having from 1 to 6 ca...
|
|
WO/2004/080377A2 |
This invention relates to compounds of the general formula (I) useful as modulators of the KCNQ channel, to pharmaceutical compositions comprising these compounds, and to methods of treatment herewith.
|
|
WO/2004/078144A2 |
The present invention relates to Diphenylethylene Compounds and compositions comprising a Diphenylethylene Compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering...
|
